Full Press Release Details
Eloxx Pharmaceuticals Announces Publication of Phase 2a Exaluren Data in Nonsense Mutation Alport Syndrome in the Journal of Clinical Investigation
November 18, 2026
Eloxx Pharmaceuticals Announces Publication of Phase 2a Exaluren Data in Nonsense Mutation Alport Syndrome in the Journal of Clinical Investigation Accessibility Statement Skip Navigation First-in-human evidence of exaluren-mediated readthrough of collagen IV in patients with nonsense mutation Alport syndromeKidney biopsies showed increased collagen IV abundance and partially improved podocyte morphology in all three participantsExaluren was well tolerated, with no serious adverse events, nephrotoxicity or ototoxicityPublished findings support the ongoing Phase 2b EXACT studyARLINGTON, Mass., Nov. 18, 2026 /PRNewswire/ — Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), a clinical-stage biopharmaceutical company developing exaluren…